480 related articles for article (PubMed ID: 18949356)
21. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Lakka SS; Gondi CS; Dinh DH; Olivero WC; Gujrati M; Rao VH; Sioka C; Rao JS
J Biol Chem; 2005 Jun; 280(23):21882-92. PubMed ID: 15824107
[TBL] [Abstract][Full Text] [Related]
22. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
[TBL] [Abstract][Full Text] [Related]
23. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.
Raghu H; Lakka SS; Gondi CS; Mohanam S; Dinh DH; Gujrati M; Rao JS
PLoS One; 2010 Aug; 5(8):e12458. PubMed ID: 20805979
[TBL] [Abstract][Full Text] [Related]
24. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
25. uPAR and cathepsin B shRNA impedes TGF-β1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway.
Gogineni VR; Gupta R; Nalla AK; Velpula KK; Rao JS
Cell Death Dis; 2012 Dec; 3(12):e439. PubMed ID: 23222509
[TBL] [Abstract][Full Text] [Related]
26. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
27. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
28. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Senthilkumar K; Arunkumar R; Elumalai P; Sharmila G; Gunadharini DN; Banudevi S; Krishnamoorthy G; Benson CS; Arunakaran J
Cell Biochem Funct; 2011 Mar; 29(2):87-95. PubMed ID: 21308698
[TBL] [Abstract][Full Text] [Related]
29. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
30. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
31. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Kunigal S; Lakka SS; Gondi CS; Estes N; Rao JS
Int J Cancer; 2007 Nov; 121(10):2307-16. PubMed ID: 17657740
[TBL] [Abstract][Full Text] [Related]
32. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
33. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.
Kunigal S; Gondi CS; Gujrati M; Lakka SS; Dinh DH; Olivero WC; Rao JS
Int J Oncol; 2006 Dec; 29(6):1349-57. PubMed ID: 17088972
[TBL] [Abstract][Full Text] [Related]
34. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
35. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.
Tummalapalli P; Spomar D; Gondi CS; Olivero WC; Gujrati M; Dinh DH; Rao JS
Int J Oncol; 2007 Nov; 31(5):1039-50. PubMed ID: 17912429
[TBL] [Abstract][Full Text] [Related]
36. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway.
Gondi CS; Kandhukuri N; Dinh DH; Gujrati M; Rao JS
Int J Oncol; 2007 Jul; 31(1):19-27. PubMed ID: 17549401
[TBL] [Abstract][Full Text] [Related]
38. TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion.
Min HJ; Lee Y; Zhao XF; Park YK; Lee MK; Lee JW; Kim S
Cell Signal; 2014 Feb; 26(2):398-408. PubMed ID: 23978400
[TBL] [Abstract][Full Text] [Related]
39. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]